Clinical perspective: Although thrombolytic therapy offers important, often life-preserving benefits to many AMI patients, its effectiveness is limited in several crucial respects: it does not achieve reperfusion in a substantial percentage of patients, nor does it reduce the underlying coronary lesion. In addition, its effectiveness cannot be predicted or reliably assessed by currently available noninvasive means in many AMI patients.
|Original language||English (US)|
|Journal||American Journal of Cardiology|
|Issue number||10 PART II|
|State||Published - Jan 1 1988|
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine